We are thrilled to announce the launch by WuXi of an online platform dedicated to rare diseases, Boshi 360 (Doctor 360, www.boshi360.com).  As the first of its kind in China developed by a leading R&D-driven industry organization, Boshi 360 is designed to be a central portal which will benefit the 16.8 million Chinese patients devastated by rare diseases.  By utilizing WuXi’s world leading lab testing platform, Boshi 360 will provide a one-stop service for patients with rare diseases – from medical information to diagnostics and treatment options, and access to patient supporting communities.

Through access to the most advanced international databases and WuXi’s global resources, Boshi 360 also aims to provide the most-in-depth knowledge, most comprehensive resources, and most professional services for this unmet medical need.  This will be of particular importance in China, where little awareness, government support, and regulatory guideline exist.

At WuXi, our mission is to leverage our R&D capabilities platform and our global resources to create broad alliances with R&D organizations, hospitals and patients.  Through our collective efforts, we hope to be able to accelerate rare disease R&D, and bring more effective treatments closer to patients as part of our corporate goal of Better Medicines Faster.


Related links:

Webinar: The Unique Challenges and Opportunities in Rare Disease R&D
Foundation Medicine and WuXi Collaborate to Offer Best-in-Class Comprehensive Genomic Profiling in China